We plan to begin with a focus on the pathology of Alzheimer's Disease (AD). A number of neurological diseases share aspects that make them especially promising candidates for our approach. One such commonality arises from the extraordinary complexity of the organ affected—the brain has been described as possibly the most complex structure in the universe! The pathology of AD is correspondingly complex and multifaceted, exhibiting a variety of macroscopic and microscopic features, affecting different brain structures to different degrees as it progresses, causing a shifting array of symptoms as it extends to specific areas of the brain.

Adding to the confusion is the tendency of demented patients to show periods of worsening or improvement related to factors: medical conditions like infections that may come and go, medication side-effects, daily biological rhythm, depression, fatigue, stress, etc. Despite the long-term prospect of progressive disability ending in death, short-term clinical changes may be difficult to predict or understand. In this context, the limited usefulness for patients of such treatments as are currently available—typically yielding partial and temporary benefits, sometimes only slowing the rate of decline—may prove hard to assess with confidence. This aspect of AD and its treatments increases the likelihood of using medications in combinations that raise the risk of unanticipated drug interactions making matters worse. 

Furthermore, we plan to develop an entirely new imaging technology intended for medical and research applications. We intend to produce a small-animal imager that will allow the pharmaceutical or clinical researcher to study and perform tests on animals without having to euthanize them. We intend to be the first medical imaging manufacturer to produce a product that is, essentially, not harmful to laboratory animals.